Innovation Pharmaceuticals (IPIX) stock price, revenue and financials

$38.9 M

IPIX Mkt cap, 08-Oct-2018

Innovation Pharmaceuticals Net income (FY, 2018)-16.4 M

Innovation Pharmaceuticals EBIT (FY, 2018)-13.9 M

Innovation Pharmaceuticals Cash, 30-Jun-20182.4 M

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018
R&D expense	6.3m	10.5m	9.0m	12.8m	11.4m
General and administrative expense	872.0k	1.2m	1.9m	1.3m	1.4m
Operating expense total	8.0m	13.0m	12.7m	15.3m	13.9m
EBIT	(8.0m)	(13.0m)	(12.7m)	(15.3m)	(13.9m)
Interest expense	210.0k	202.0k	202.0k	202.0k	202.0k
Interest income	1.0k	4.0k	4.0k	2.0k	1.0k
Pre tax profit	(8.2m)	(13.1m)	(12.9m)	(15.5m)	(16.4m)
Net Income	(8.2m)	(13.1m)	(12.9m)	(15.5m)	(16.4m)

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q3, 2018
R&D expense	1.9m	2.3m	1.8m	2.1m	3.0m	2.3m	2.7m	3.2m	1.8m
General and administrative expense	244.0k	275.0k	339.0k	352.0k	249.0k	362.0k	344.0k	331.0k	295.0k
Operating expense total	2.2m	2.6m	2.2m	3.3m	3.7m	3.0m	3.3m	3.9m	2.4m
EBIT	(2.7m)	(2.8m)	(2.5m)	(3.3m)	(3.7m)	(3.0m)	(3.3m)	(3.9m)	(2.4m)
Interest expense	51.0k	51.0k	51.0k	50.0k	51.0k	51.0k	50.0k	51.0k	51.0k
Interest income	1.0k	1.0k	1.0k	1.0k	1.0k	1.0k	1.0k
Pre tax profit	(2.8m)	(2.9m)	(2.6m)	(3.3m)	(3.7m)	(3.0m)	(3.4m)	(3.9m)	(2.4m)
Net Income	(2.8m)	(2.9m)	(2.6m)	(3.3m)	(3.7m)	(3.0m)	(3.4m)	(3.9m)	(2.4m)

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018
Cash	5.0m	8.4m	6.3m	4.1m	2.4m
Current Assets	5.6m	8.8m	6.7m	4.5m	2.6m
Total Assets	10.9m	14.3m	11.4m	9.1m	6.5m
Accounts Payable			42.2m
Current Liabilities	9.6m	7.3m	8.5m	10.6m	8.7m
Total Liabilities	9.6m	7.3m	8.5m	10.6m	8.7m
Additional Paid-in Capital	29.2m	48.2m	57.0m	68.3m	83.7m
Retained Earnings	(28.0m)	(41.2m)	(54.0m)	(69.6m)	(85.9m)
Total Equity	1.2m	7.0m	3.0m	(1.5m)	(2.2m)
Financial Leverage	9 x	2 x	3.9 x	-6.2 x	-3 x

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q3, 2018
Cash	7.1m	9.5m	10.8m	7.8m	6.2m	5.3m	5.6m	3.9m	5.6m	1.3m
Current Assets	7.2m	9.6m	11.4m	8.0m	6.4m	5.8m	6.2m	4.1m	5.7m	1.5m
Total Assets	12.5m	14.9m	17.1m	13.5m	11.9m	11.3m	10.9m	8.8m	10.5m	5.8m
Current Liabilities	8.0m	7.7m	7.3m	7.5m	7.6m	8.4m	8.8m	8.7m	9.3m	9.5m
Total Liabilities					7.6m	8.4m	8.8m	8.7m	9.3m	9.5m
Additional Paid-in Capital	36.9m	42.3m	47.8m	49.8m	51.3m	53.6m	59.2m	60.5m	65.5m	77.3m
Retained Earnings	(32.4m)	(35.2m)	(38.1m)	(43.7m)	(47.1m)	(50.8m)	(57.0m)	(60.4m)	(64.3m)	(81.1m)
Total Equity	4.5m	7.1m	9.8m	6.0m	4.3m	2.9m	2.1m	136.0k	1.2m	(3.7m)
Financial Leverage	2.8 x	2.1 x	1.7 x	2.2 x	2.8 x	3.9 x	5.1 x	64.6 x	8.9 x	-1.5 x

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018
Net Income	(8.2m)	(13.1m)	(12.9m)	(15.5m)	(16.4m)
Accounts Payable	815.0k	(826.0k)	1.7m	1.2m	(1.5m)
Cash From Operating Activities	(7.5m)	(13.1m)	(9.9m)	(11.7m)	(13.3m)
Purchases of PP&E	(43.0k)	(9.0k)	(68.0k)
Cash From Investing Activities	(2.6m)	(459.0k)	(414.0k)	(336.0k)	(104.0k)
Cash From Financing Activities	12.2m	17.0m	8.2m	9.9m	11.7m
Interest Paid	259.0k	366.0k	235.0k	44.0k	171.0k

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Net Income	(2.8m)	(2.9m)	(2.6m)	(5.9m)	(9.6m)	(3.0m)	(3.4m)	(3.9m)
Accounts Payable				259.0k	1.3m
Cash From Operating Activities				(4.6m)	(7.7m)
Purchases of PP&E					(68.0k)
Cash From Investing Activities				(217.0k)	(348.0k)
Cash From Financing Activities				2.6m	5.0m
Interest Paid				29.0k	74.0k

Report incorrect company information

View Innovation Pharmaceuticals profile

Competitors

Bellerophon Therapeutics

Healthcare - Public

Hedgepath Pharmaceuticals

Healthcare - Public

Heron Therapeutics

Healthcare - Public

Alexion Pharmaceuticals

Healthcare - Public

Compare competitors